Rising Serum Lactate Dehydrogenase Often Caused by Granulocyte-or Granulocyte-Macrophage Colony Stimulating Factor and not Tumor Progression in Patients with Lymphoma or Myeloma

References

• Schneider R., Seibert K., Passe S., Straus D. Prognostic significance of serum lactate dehydrogenase in malignant lymphoma. Cancer 1980; 46: 139–143
   PubMed Web of Science ®Google Scholar
• Shipp M. A., Harrington D. P., Klatt M. M., Jochelson M. S., Pincus G. S., Marshall J. L., Rosenthal D. S., Skarin A. T., Canellos G. P. Identification of major prognostic subgroups of patients with diffuse large cell lymphoma treated with m-BACOD or M-BACOD. Ann. Int. Med. 1986; 104: 757–765
   PubMed Web of Science ®Google Scholar
• Velasquez W. S., Jagannath S., Tucker S. L., Fuller L. M., North L. B., Redman J. R., Swan F., Hagemeister F. B., McLaughlin P., Cabanillas F. C. Risk classification as the basis for clinical staging of diffuse large-cell lymphoma derived from 10-year survival data. Blood 1989; 74: 551–557
   PubMed Web of Science ®Google Scholar
• Swan F., Jr., Velasquez W. S., Tucker S., Redman J. R., Rodriquez M. A., McLaughlin P., Hagemeister F. B., Cabanillas F. A new serologic staging system for large-cell lymphomas based on initial beta 2-microglobulin and lactate dehydrogenase levels. J. Clin. Oncol. 1989; 7: 1518–1527
   PubMed Web of Science ®Google Scholar
• Coiffier B., Gisselbrecht C., Vose J., Tilly H., Herbrecht R., Bosly A., Armitage J. Prognostic factors in aggressive malignant lymphomas: Description and validation of a prognostic index that could Identify patients requiring a more intensive therapy. J. Clin. Oncol. 1991; 9: 211–219
   PubMed Web of Science ®Google Scholar
• Vitolo U., Bertini M., Brusamolino E., Cavallero G. B., Comotti B., Gallo E., Ghio R., Levis A., Luxi G., Meneghini V., Novero D., Orsucci L., Rota-Scalabrini D., Tarrella C., Todeschini G., Viero P., Tiziano B., Bernasconi C., Perona G., Pileri A., Resegotti L. MACOP-B treatment in diffuse large-cell lymphoma: Identification of prognostic groups in an Italian multicen-ter study. J. Clin. Oncol. 1992; 10: 219–227
   PubMed Web of Science ®Google Scholar
• Rodriguez J., Cabanillas F., McLaughlin P., Swan F., Rodriguez M., Hagemeister F., Romaguera J. A proposal for a simple staging system for intermediate grade lymphoma and immunoblastic lymphoma based on the tumor score. Ann. Oncol 1992; 3: 711–717
   PubMed Web of Science ®Google Scholar
• Rodriguez J., Cabanillas F., McLaughlin P., Swan F., Rodriguez M., Hagemeister F., Romaguera J. A predictive model for aggressive Non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma prognostic factors project. N. Eng. J. Med. 1993; 329: 987–994
   PubMed Web of Science ®Google Scholar
• Straus D., Gaynor J., Myers J., Merke D., Caravelli J., Chapman D., Yahalom J., Clarkson B. Prognostic factors among 185 adults with newly diagnosed advanced Hodgkin's disease treated with alternating potentially noncross-resistant chemotherapy and intermediate-dose radiation therapy. J. Clin. Oncol 1990; 8: 1173–1186
   PubMed Web of Science ®Google Scholar
• Dimopoulos M., Barlogie B., Smith T., Alexanian R. High serum lactate dehydrogenase level as a marker for drug resistance and short survival in multiple myeloma. Ann. Intern. Med. 1991; 115: 931–935
   PubMed Web of Science ®Google Scholar
• Weeks J. C., Yeap B. Y., Canellos G. P., Shipp M. A. Value of follow-up procedures in patients with large-cell lymphoma who achieve a complete remission. J. Clin. Oncol. 1991; 9: 1196–203
   PubMed Web of Science ®Google Scholar
• Nemunaitis J., Rabinowe S. N., Singer J. W. Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer. N. Engl. J. Med. 1991; 324: 1773–1778
   PubMed Web of Science ®Google Scholar
• Herrmann F., Schulz G., Lindermann A. Hematopoietic responses in patients with advanced malignancy treated with recombinant human granulocyte-macrophage colony-stimulating factor. J. Clin. Oncol 1989; 7: 159–167
   PubMed Web of Science ®Google Scholar
• Maiche A. G., Muhonen T., Porkka K. Lactate dehydrogenase changes during granulocyte colony-stimulating factor treatment. Lancet 1992; 340: 853
   PubMed Web of Science ®Google Scholar
• Fossa S., Poulsen J., Aaserud A. Alkaline phosphatase and lactate dehydrogenase changes during leucocytosis induced by G-CSF in testicular cancer. Lancet 1992; 340: 1544
   PubMed Web of Science ®Google Scholar
• Kaplan E. L., Meier P. Non-parametric estimation from incomplete observations. J. American Statistical Association 1958; 53: 257–481
   Google Scholar
• Cabanillas F., McLaughlin P., Hagemeister F., Swan F., Rodriguez M., Romaguera J., Majlis A., Jendiroba D., Rodriguez J. Improvement in survival and disease free survival of intermediate grade (IGL) and immunoblastic lymphomas (IBL) treated with the novel ATT regimen. Proceedings American Society Clinical Oncology 1994; 13: 1323a
   Google Scholar
• Rodriguez M., Cabanilla F., Hagemeister F., McLaughlin P., Romaguera J., Swan F., Velasquez W. MINE/ESHAP: A novel and effective salvage combination (SC) for lymphoma. Proceedings of the American Society for Clinical Oncology 1992; 11: 1114a
   Google Scholar
• Younes A., Sarris A., McLaughlin P., Romaguera J., Jendiroba D., Swan F., Rodriguez M., Hagermeister F., Moore D., Cabanillas F. Phase II trial of Taxol given as 3-hour infusion schedule every 3 weeks in relapsed non-Hodgkin's lymphoma (NHL). Proceedings of the American Society for Clinical Oncology 1994; 13: 1267a
   Google Scholar
• Kantarjian H., O'Brien S., Beran M., Escudier S., Pierce S., Estey E., Koller C., Robertson B., Andreef M., Keating M., Bowman P., Murphy S., Freireich E. Modified Burkitt regimen for adult acute lymphocytic leukemia (ALL)—The Hyper-CVAD program. Blood 1993; 82(Suppl 1)329a
   Google Scholar
• Velasquez W., Hagemeister F., McLaughlin P., Swan F., Rodriguez M., Romaguera J., Cabanillas F. E-SHAP: an effective treatment for refractory and relapsing lymphoma. Proceedings of the American Society for Clinical Oncology 1992; 11: 1111a
   Google Scholar
• Klimo P., Connors J. M. MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma. Ann. Intern. Med. 1985; 102: 596–602
   PubMed Web of Science ®Google Scholar
• Schneider A. M., Straus D. J., Schluger A. E., Lowenthal D. A., Koziner B., Lee B. J., Wong G., Clarkson B. D. Treatment results with an aggressive chemotherapeutic regimen (MACOP-B) for intermediate-and some high-grade non-Hodgkin's lymphomas. J. Clin. Oncol 1990; 8: 94–102
   PubMed Web of Science ®Google Scholar
• Litam P., Friedman H., Loughran T. Splenic extramedullary hematopoiesis in a patient perceiving intermittently administered granulocyte colony-stimulating factor. Ann. Intern. Med. 1993; 118: 954–955
   PubMed Web of Science ®Google Scholar
• McCarthy C. F., Fraser I. D., Read A. E. Plasma lactate dehydrogenase in megaloblastic anaemia. J. Clin. Pathol 1966; 19: 51–54
   PubMed Web of Science ®Google Scholar